Global LHRH for Prostate Treatment Market Insights, Forecast to 2028

Market Analysis and Insights: Global LHRH for Prostate Treatment Market
Due to the COVID-19 pandemic, the global LHRH for Prostate Treatment market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Leuprolide accounting for % of the LHRH for Prostate Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Age < 55 segment is altered to an % CAGR throughout this forecast period.
China LHRH for Prostate Treatment market size is valued at US$ million in 2021, while the US and Europe LHRH for Prostate Treatment are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe LHRH for Prostate Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of LHRH for Prostate Treatment include AbbVie, Astella, Johnson & Johnson, Sanofi and Merck Group, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global LHRH for Prostate Treatment Scope and Segment
LHRH for Prostate Treatment market is segmented by Type and by Application. Players, stakeholders, and other participants in the global LHRH for Prostate Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Leuprolide
Goserelin
Triptorelin
Other
Segment by Application
Age < 55
Age 55-75
Age > 75
By Company
AbbVie
Astella
Johnson & Johnson
Sanofi
Merck Group
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE